trial · primary record
Drug: EDIT-401
Heterozygous Familial Hypercholesterolemia (HeFH)
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 56 |
| Primary completion | 2031-07 |
| Primary endpoint | Part 1: Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) |
| Registry ID | NCT07894887 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:54.738Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07894887
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.